Global Hepatitis C Drugs Market to Reach US$ 7,351.7 Mn; Increasing Demand for Hepatitis C Drugs Will Favor Growth, says Fortune Business Insights

 The global “hepatitis C drugs market” will derive growth impetus from the high prevalence of hepatitis C across the world. According to a report published by Fortune Business Insights, titled “Hepatitis C Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 7,866.6 Mn in 2018. Fortune Business Insights states that the market is projected to reach US$ 7,351.7 Mn by 2026, exhibiting a CAGR of -0.9% in the forecast period.

Hepatitis C requires oral injections and dosages on a weekly basis, and it also has several side effects that can also lead to permanent damage. Increasing clinical trials and successful drug clearances have aided the overall growth of the global hepatitis C market. Increasing number of regulatory approvals will boost the global hepatitis C market in the forthcoming years.

Hepatitis C is a viral infection that causes severe damage such as inflammation of the liver and can spread through contaminated blood. The advanced stages of hepatitis C can also lead to liver damage, thereby creating severe health risks. The severity of hepatitis C has created a huge emphasis on the research and development of drugs associated with the treatment of this disease. Several new drugs have been launched in recent times, due to the high prevalence of hepatitis C across the world.

Request a Sample Copy of the Research Report

Huge Hepatitis C Patient Pool Will Offer Growth Opportunities for the Market in North America

The high prevalence of hepatitis C has created a need for efficient drugs at low cost. Fortune Business Insights has identified increasing hepatitis C incidence as a primary growth driver. The increased adoption of hepatitis C drugs will favor the growth of the market in North America. Fortune Business Insights has predicted that the hepatitis C drugs market in North America will witness considerable growth, driven by the high demand for hepatitis C drugs. Furthermore, recent drug advancements will fuel the demand for related drugs, subsequently aiding market growth. Fortune Business Insights states that the hepatitis C drugs market in North America was valued at US$ 3,736.6 Mn in 2018.

Fortune Business Insights profiles a few of the prominent companies that are operating in the global market. Some of the leading companies that have established standout market positions are AbbVie Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd, and Vertex Pharmaceuticals Incorporated.

Have Any Query? Ask Our Experts

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Please Visit: https://www.fortunebusinessinsights.com/industry-reports/hepatitis-c-drug-market-101562

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

Comments

Post a Comment

Popular posts from this blog

Health Insurance Market to Exhibit 5.5% CAGR till 2028; Bharti AXA General Insurance’s Health AdvantEDGE to Provide Benefits amid COVID-19

  The global “ health insurance market ” size is set to reach USD 3,038.6 billion by 2028. Fortune Business Insights™ presented this information in a new study, titled, ““Health Insurance Market, 2021-2028.” The study further mentions that the market stood at USD 1,966.6 billion in 2020. It would exhibit a CAGR of   5.5%   in the forecast period between 2021-2028. Several government and private agencies are introducing new schemes to attract more customers. In December 2020, for instance, ICICI Lombard unveiled its latest ‘ICICI Lombard Complete Health Insurance’ featuring unique benefits and health plans.  Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/health-insurance-market-101985 COVID-19 Pandemic: Relaxations of Premiums May Hamper Growth The COVID-19 pandemic has compelled various companies to strengthen their existing schemes for meeting the high demand. They have started introducing new subscriptions including COVID-19 prote
Read more

Anti-obesity Drugs Market to Showcase 10.1% CAGR till 2027; Rising Concerns Regarding Obesity and Overweight Globally to Drive Growth, says Fortune Business Insights™

  The global “ anti-obesity drugs market ” size is set to grow significantly owing to the ever-increasing prevalence of obesity among the global population, observes Fortune Business Insights™ in its report, titled, “Anti-obesity Drugs Market Size, Share & COVID-19 Impact Analysis, By Type (Prescription Drugs and OTC Drugs), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size was USD 1,520.2 million in 2019 and is anticipated to reach USD 3,421.0 million by 2027, exhibiting a CAGR of 10.1% during the forecast period. Request a Sample Copy of the Research Report https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783 Drivers & Restraints- Rising Cases of Obesity Worldwide to Drive Growth The increasing cases of obesity and overweight among patients globally due to inactive lifestyles and poor eating habits are anticipated to drive the anti-obesity drugs market growth. For instance,
Read more

Deep Brain Stimulation Devices Market to Reach USD 1,676.8 Million by 2026; Launch of Vercise Gevia Deep Brain Stimulation Systems to Boost Growth, says Fortune Business Insights™

  The global “ deep brain stimulation devices ” market size is expected to reach USD 1,676.8 million by 2026, exhibiting a CAGR of 11.6% during the forecast period. The growing awareness among the population concerning various neurological ailments will be a crucial factor in accelerating the deep brain stimulation devices market revenue during the forecast period. In addition, the increasing cases of epilepsy around the world will fuel demand for deep brain stimulation devices in the forthcoming years. According to the World Health Organization, Epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. In addition, the increasing prevalence of neurological diseases in low and middle-income countries will propel the growth of the market in the foreseeable future. For instance, as per the World Health Organization survey, nearly 80% of peo
Read more